CytoMed Therapeutics (GDTC) News Today $1.84 +0.06 (+3.09%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock GDTC Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period CytoMed Therapeutics Launches ATM Offering Program to Boost GrowthAugust 19 at 6:30 AM | tipranks.comCytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering ProgramAugust 18, 2025 | gurufocus.comCytoMed Therapeutics Limited Enters At-the-Market Sales Agreement for Up to $4.3 Million in SharesAugust 18, 2025 | quiverquant.comQCytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering ProgramAugust 18, 2025 | gurufocus.comCytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program | GDTC Stock NewsAugust 18, 2025 | gurufocus.comCytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering ProgramAugust 18, 2025 | globenewswire.comUpdate On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological MalignanciesJuly 21, 2025 | globenewswire.comCytoMed Therapeutics Issues Shares to Executives as CompensationJuly 3, 2025 | tipranks.comCytoMed Therapeutics Schedules AGM for June 2025May 16, 2025 | tipranks.comCytoMed Therapeutics Reports 2024 Financial Results and Clinical ProgressMay 7, 2025 | tipranks.comCytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate UpdatesApril 28, 2025 | globenewswire.comCytoMed Therapeutics announces Chairman's Letter to the Company's shareholdersFebruary 6, 2025 | globenewswire.comCytoMed Therapeutics Expands Leadership Amid Strategic GrowthDecember 5, 2024 | tipranks.comCytoMed Therapeutics Limited (GDTC)July 19, 2024 | finance.yahoo.comCytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid CancersJuly 17, 2024 | globenewswire.comCytoMed Therapeutics Ltd GDTCMarch 27, 2024 | morningstar.comMCytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage RegenerationMarch 20, 2024 | finance.yahoo.comCYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision TherapiesMarch 18, 2024 | finanznachrichten.deCytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision TherapiesMarch 18, 2024 | markets.businessinsider.comCytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision TherapiesMarch 18, 2024 | globenewswire.comCytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and RepairMarch 4, 2024 | globenewswire.comCytoMed Therapeutics (Nasdaq:GDTC) HeadlineTrading was temporarily halted for "GDTC" at 09:02 AM with a stated reason of "LULD pause." Trading set to resume at 09:02 AM. February 7, 2024 | marketbeat.comCytoMed Therapeutics (Nasdaq:GDTC) HeadlineTrading was temporarily halted for "GDTC" at 09:02 AM with a stated reason of "LULD pause."...February 7, 2024 | marketbeat.comCytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo PersistencyAugust 15, 2023 | finance.yahoo.comCytoMed Therapeutics Ltd (GDTC)August 8, 2023 | investing.comInsiders Rewarded With S$77k Addition To Investment As CytoMed Therapeutics Stock Hits US$51mAugust 8, 2023 | finance.yahoo.comCytoMed Therapeutics Announces U.S. Patent Granted For its Licensed, Novel CAR-Gamma Delta T Cell TechnologyAugust 8, 2023 | finance.yahoo.comChinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell TechnologyAugust 8, 2023 | finance.yahoo.comWhy Is CytoMed Therapeutics (GDTC) Stock Up 157% Today?July 11, 2023 | investorplace.comCytoMed Therapeutics (Nasdaq:GDTC) HeadlineTrading was temporarily halted for "GDTC" at 10:05 AM with a stated reason of "LULD pause."...May 9, 2023 | marketbeat.comCytoMed Therapeutics (Nasdaq:GDTC) HeadlineTrading was temporarily halted for "GDTC" at 10:05 AM with a stated reason of "LULD pause."...May 9, 2023 | marketbeat.com Get CytoMed Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter. Email Address GDTC Media Mentions By Week GDTC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GDTC News Sentiment▼0.210.54▲Average Medical News Sentiment GDTC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GDTC Articles This Week▼60▲GDTC Articles Average Week Get CytoMed Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AIMDW News Today BCTXW News Today ENGNW News Today FBIOP News Today GLPG News Today GOVXW News Today INDV News Today INCR News Today JSPRW News Today LEXXW News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GDTC) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access